Today: 11 June 2026
Browse Category

NASDAQ:FOSL 23 August 2025 - 16 October 2025

Fossil Group (FOSL) Stock’s Wild 2025 Ride: Skyrockets on Turnaround Hopes, Stumbles on Debt Fears

Fossil Group (FOSL) Stock’s Wild 2025 Ride: Skyrockets on Turnaround Hopes, Stumbles on Debt Fears

Fossil Group shares jumped over 40% to $3.75 on Oct. 15 after reporting a surprise profit and India IPO rumors, then fell 40% the next day on renewed debt concerns. Year-to-date, the stock is up 62%, far outpacing industry peers. The company is restructuring $150 million in debt and exploring a $300–$400 million India unit IPO. Q2 results showed a swing to $8.5 million operating profit despite a 16% sales drop.
16 October 2025
·
2025’s Most Popular Men’s and Women’s Watches – Luxury Icons, Smartwatch Superstars, Fashion Favorites & Affordable Gems

2025’s Most Popular Men’s and Women’s Watches – Luxury Icons, Smartwatch Superstars, Fashion Favorites & Affordable Gems

Swiss watch exports hit a record CHF 26.7 billion in 2023. Rolex surpassed CHF 10 billion in annual revenue, selling about 1.24 million watches and capturing 30% of the market. The Big Four brands account for nearly 44% of Swiss watch market value. Smartwatches reached 455 million users worldwide, with Apple holding a 21% share.
23 August 2025
······

Stock Market Today

  • US Stocks Rise on AI Gains as Oil Prices Steady Amid Iran War Concerns
    June 11, 2026, 10:56 AM EDT. US stock indices climbed on Thursday, led by artificial intelligence (AI) stocks driving gains in chipmakers like Marvell Technology (+4.3%) and Intel (+10.4%). The S&P 500 rose 0.6%, with the Nasdaq up 0.8% and the Dow gaining 0.7%. Despite escalating tensions in the Iran war, oil prices held steady, with Brent crude easing 1.1% to $92.08 per barrel and U.S. crude down 0.6% to $89.52. The market showed resilience despite concerns over inflation pressures fueled by higher wholesale prices and renewed geopolitical risks. Oracle fell 10.3% after announcing substantial planned borrowing and equity sales to fund AI investments, reflecting investor caution on aggressive spending amidst uncertainty.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Go toTop